News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
121,479 Results
Type
Article (5044)
Company Profile (30)
Press Release (116405)
Section
Business (42262)
Career Advice (128)
Deals (7445)
Drug Delivery (6)
Drug Development (15303)
Employer Resources (15)
FDA (2689)
Job Trends (3033)
News (66271)
Policy (4857)
Tag
Academia (304)
Africa (108)
Alabama (4)
Alliances (5446)
ALS (3)
Alzheimer's disease (154)
Antibody-drug conjugate (ADC) (12)
Approvals (2683)
Arizona (14)
Artificial intelligence (4)
Asia (6653)
Australia (922)
Bankruptcy (43)
Best Places to Work (2616)
C2C Services and Suppliers (10796)
California (137)
Canada (189)
Cancer (28)
Career advice (113)
Cell therapy (3)
China (7)
Clinical research (12458)
Collaboration (9)
Colorado (9)
Connecticut (4)
COVID-19 (452)
Cystic fibrosis (18)
Data (5)
Delaware (8)
Diagnostics (1148)
Drug pricing (3)
Duchenne muscular dystrophy (4)
Earnings (30672)
Employer branding (3)
Employer resources (12)
Europe (15085)
Events (21168)
FDA (2693)
Florida (12)
Funding (7)
Gene therapy (9)
GLP-1 (68)
Government (574)
Healthcare (3775)
Hotbed/Location (85070)
Idaho (6)
Illinois (28)
Indiana (37)
Infectious disease (455)
Inflammatory bowel disease (14)
Interviews (20)
IPO (4647)
Job creations (429)
Job search strategy (99)
Kansas (24)
Layoffs (41)
Legal (694)
Liver cancer (14)
Maine (26)
Management (5)
Manufacturing (6)
Maryland (31)
Massachusetts (83)
Medical device (2787)
Medtech (2787)
Mergers & acquisitions (2761)
Metabolic disorders (15)
NASH (3)
Neuroscience (161)
New Jersey (19)
New York (9)
NextGen Class of 2024 (1037)
Non-profit (659)
North Carolina (26)
Obesity (9)
Opinion (17)
Parkinson's disease (3)
Pennsylvania (11)
People (4135)
Phase I (3140)
Phase II (5194)
Phase III (5022)
Postmarket research (620)
Preclinical (1040)
Rare diseases (20)
Real estate (672)
Recruiting (8)
Regulatory (3690)
Reports (5)
Research institute (292)
Resumes & cover letters (12)
RSV (3)
Series A (4)
South America (156)
Startups (334)
Texas (9)
United States (532)
Vaccines (77)
Washington State (32)
Weight loss (7)
Date
Today (1)
Last 7 days (84)
Last 30 days (314)
Last 365 days (8796)
2024 (4904)
2023 (9387)
2022 (12147)
2021 (14122)
2020 (12624)
2019 (8298)
2018 (6397)
2017 (5673)
2016 (4920)
2015 (6331)
2014 (4075)
2013 (2930)
2012 (3341)
2011 (3740)
2010 (3290)
121,479 Results for "90".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical Trials
Bright Peak Therapeutics, a biotechnology company developing next-generation, multifunctional immunotherapies, announced that it raised $90 million in a Series C financing.
June 11, 2024
·
2 min read
BioMidwest
Case Studies of Patients with Diabetic Foot Ulcers Showed 90 to 100 Percent Wound Closure at 12 weeks Following Weekly Treatment with Novel OMEZA® OCM™
Omeza®, a regenerative skincare company that develops marine-based therapies for nonhealing wounds that are hard to treat, presented three case studies showing that diabetic foot ulcers treated weekly with Omeza® OCM™ demonstrated 90 to 100 percent wound closure at 12 weeks.
June 12, 2024
·
4 min read
Biotech Beach
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
MannKind Corporation announced that the 17-week endpoint results from the INHALE-3 study will be presented during a 90-minute symposium and livestream on Saturday, June 22, at the American Diabetes Association’s 84th Scientific Sessions.
June 5, 2024
·
4 min read
Philips Zenition 90 Motorized receives FDA 510(k) clearance, helping clinicians deliver high quality care with a high-powered and fast motorized mobile C-arm
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Philips Image Guided Therapy Mobile C-arm System 9000 – Zenition 90 Motorized, designed to help clinicians deliver high-quality care to more patients.
June 17, 2024
·
4 min read
Biotech Bay
Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
Astellas Pharma Inc. announced the opening of a new $90 million, state-of-the-art center at 480 Forbes Boulevard in South San Francisco, CA.
May 8, 2024
·
3 min read
Drug Development
AstraZeneca, Sanofi’s Beyfortus 90% Effective at Preventing RSV Hospitalizations: CDC
AstraZeneca and Sanofi’s respiratory syncytial virus immunizing antibody Beyfortus reached effectiveness of 90% against infection-related hospitalization in infants, according to the Centers for Disease Control and Prevention.
March 8, 2024
·
2 min read
·
Tristan Manalac
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
Enliven Therapeutics, Inc. today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $90 million, before deducting offering expenses.
March 19, 2024
·
10 min read
Drug Development
Immutep Announces First Clinical Data from 90mg Dosing of Efti
Immutep Limited today announces safety and initial efficacy data from the first ever 90mg dosing of eftilagimod alpha (efti) in combination with weekly paclitaxel in patients from the safety lead-in (N=6) of the AIPAC-003 Phase II/III trial.
March 5, 2024
·
3 min read
Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients
Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial.
February 15, 2024
·
3 min read
Press Releases
Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
July 18, 2024
·
9 min read
1 of 12,148
Next
